American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 946-951 , December 2007

A Randomized Trial of a 6-Week Course of Celecoxib on Proteinuria in Diabetic Kidney Disease

  • Marvin Sinsakul, MD

      Affiliations

    • Rush University Medical Center, Chicago, IL
    • Corresponding Author InformationAddress correspondence to Marvin Sinsakul, MD, Rush University Medical Center, 1426 W Washington Blvd, Chicago, IL 60607.
    • ,
  • Mohammed Sika, PhD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN
    • ,
  • Roger Rodby, MD

      Affiliations

    • Rush University Medical Center, Chicago, IL
    • ,
  • John Middleton, MD

      Affiliations

    • Duke University Medical Center, Durham, NC.
    • ,
  • Yu Shyr, PhD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN
    • ,
  • Heidi Chen, PhD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN
    • ,
  • Ernest Han, MD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN
    • ,
  • Ruediger Lehrich, MD

      Affiliations

    • Duke University Medical Center, Durham, NC.
    • ,
  • Stephen Clyne, MD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN
    • ,
  • Gerald Schulman, MD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN
    • ,
  • Raymond Harris, MD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN
    • ,
  • Julia Lewis, MD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN

Received 21 February 2007 ,Accepted 14 September 2007.

References 

  1. US Renal Data System. USRDS 2004 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases; 2004;
  2. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462
  3. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  4. Harris RC, Breyer MD. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol. 2006;1:236–245
  5. Wang JL, Cheng HF, Zhang MZ, et al. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol. 1998;275:F613–F622
  6. Cheng HF, Wang CJ, Moeckel GW, et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int. 2002;62:929–939
  7. Wang JL, Cheng HF, Sheppel S, et al. The cyclooxygenase-2 inhibitor, SC58326, decreases proteinuria and retards progression of glomerulosclerosis in the rat remnant kidney. Kidney Int. 2000;57:2334–2342
  8. Bergstein JM. Prostaglandin inhibitors in the treatment of nephrotic syndrome. Pediatr Nephrol. 1991;5:335–338
  9. Sandhu GK, Heyneman CA. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother. 2004;38:700–704
  10. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102
  11. Levey AS, Coresh J, Greene T, et al. Expressing the MDRD Study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol. 2005;16:69A;(abstr)
  12. Zhang J, Ding E, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events. JAMA. 2006;296:1619–1632
  13. Horiba N, Kumano E, Watanabe T, et al. Subtotal nephrectomy stimulates cyclooxygenase 2 expression and prostacyclin synthesis in the rat remnant kidney. Nephron. 2002;91:134–141
  14. Vallon V, Kirschenmann D, Wead LM, et al. Effect of chronic salt loading on kidney function in early and established diabetes mellitus in rats. J Lab Clin Med. 1997;130:76–82
  15. Thomson SC, Deng A, Bao D, et al. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest. 2001;107:217–224
  16. Heeg JE, De Jong PE, Vriesendorp R, et al. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol. 1990;10:94–97
  17. Chang I, Harris RC. Are all COX-2 inhibitors created equal?. Hypertension. 2005;45:178–180
  18. Frank DH, Roe DJ, Chow HS, et al. Effects of a high-selenium yeast supplement on celecoxib plasma levels: A randomized phase II trial. Cancer Epidemiol Biomarkers Prev. 2004;13:299–303
  19. Zhang J, Ding E, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrythmia events. JAMA. 2006;296:1619–1632
  20. Juurlink D, Mamdani M, Lee D, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–551

 Trial registration: www.clinicaltrials.gov; study number: NCT00065559.

PII: S0272-6386(07)01247-4

doi: 10.1053/j.ajkd.2007.09.005

American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 946-951 , December 2007

Article Tools

* Image Usage & Resolution